Table 3.

Adverse events reported by participants

	Adverse events overall (n=21 817)	Adverse events in ten sentinel villages (n=1399)
Dizziness	144 (0·7%)	6 (0·4%)
Abdominal pain	80 (0·4%)	8 (0·6%)
Diarrhoea	71 (0·3%)	10 (0·7%)
Headache	47 (0·2%)	10 (0·7%)
Muscle pain	42 (0·2%)	4 (0·3%)
Joint pain	37 (0·2%)	5 (0·4%)
Itch	24 (0·1%)	12 (0·9%)
Nausea	15 (0·1%)	3 (0·2%)
Vomiting	6 (<0·1%)	0
Other*	59 (0·3%)	0
Individuals who experienced more than one event	46 (0·2%)	0
Individuals who experienced at least one event	571 (2·6%)	58 (4·1%)

Adverse event data were collected at the second study visit 7–14 days after the baseline coadministration of azithromycin and ivermectin.

^*Other reported events included skin conditions (n=29, including 15 tinea infections and seven molluscum contagiosum), eye conditions (n=17), and other miscellaneous (n=13, including conditions such as broken knee).